Search

Your search keyword '"palivizumab"' showing total 3,715 results

Search Constraints

Start Over You searched for: Descriptor "palivizumab" Remove constraint Descriptor: "palivizumab"
3,715 results on '"palivizumab"'

Search Results

2. Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative.

3. Empfehlungen der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde zur Prophylaxe einer RSV-Infektion mit Nirsevimab.

4. Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants.

5. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.

6. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

7. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.

8. RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review.

9. Update to: Study Pre-protocol for 'BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study' [version 3; peer review: 2 approved]

10. Prévention des infections à virus respiratoire syncytial.

14. Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease

15. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

16. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

17. RSV (Respiratory Syncytial Virus)

18. Respiratory syncytial virus immunization patterns in Germany, 2015–2020

19. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

20. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.

21. Formulary Drug Reviews: Nirsevimab.

22. Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease.

23. Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice.

24. Inhaled "Muco‐Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.

25. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.

26. Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date.

27. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.

28. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States.

29. Balanced on the Biggest Wave: Nirsevimab for Newborns.

30. Clinical, Genomic, and Immunological Characterization of RSV Surge in Sydney, Australia, 2022.

31. Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.

32. Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.

33. RSV-Prophylaxe.

34. Breakthroughs in the prevention of RSV disease among infants

35. RSV vaccination during pregnancy: Finally ready for prime time: FDA approved in August of this year, the new bivalent RSV prefusion F vaccine represents a major and welcomed breakthrough, as an effective vaccine for women during pregnancy and for infant protection has eluded scientists and clinicians for 50 years

36. Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity

38. AstraZeneca Pharma net profit grows to Rs. 39.5 crore in Q4FY24

39. Personalized Tool Can Predict Infants at Increased Risk for RSV

40. Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita.

41. Protecting Infants from RSV: Understanding Guidance on New Prevention Tools.

42. Respiratory Syncytial Virus Infection: An Update.

43. Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands.

44. Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection.

45. Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors.

46. RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review

47. Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

Catalog

Books, media, physical & digital resources